help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serri, O.
Right arrow Articles by Brownell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serri, O.
Right arrow Articles by Brownell, J.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 682-687, Copyright © 1990 by Endocrine Society

ARTICLES

Long term treatment with CV 205-502 in patients with prolactin- secreting pituitary macroadenomas

O Serri, H Beauregard, J Lesage, L Pedneault, R Comtois, N Jilwan, M Somma, L Vachon and J Brownell
Service of Endocrinology, Research Center Notre-Dame Hospital, University of Montreal, Canada.

CV 205-502, a new long-acting nonergot dopamine agonist, was given to 15 patients (6 women and 9 men) with PRL-secreting pituitary macroadenomas. The compound was administered in a single daily dose for a period of 6-12 months. The treatment resulted in normalization of plasma PRL levels (less than or equal to 20 micrograms/L) in 5 of 6 women at a mean dose of 135 micrograms (range, 75-300 micrograms) and in 6 of 9 men at a mean dose of 192 micrograms (range, 75-300 micrograms). Among patients for whom computed tomographic scans were available before and after at least 6 months of therapy, definite tumor shrinkage occurred in 6 of 7 patients. Libido was improved in 5 of 6 women and in 6 of 8 men, galactorrhea disappeared in all cases (3 women and 1 man) and menses resumed in 3 of 5 women. Plasma testosterone rose to normal levels in 3 of 6 men who were not receiving testosterone injections. The PRL response to TRH was blunted in 4 of 6 patients with normalized basal PRL. Serum total cholesterol was reduced by CV 205-502 treatment in women from 5.35 +/- 0.49 to 4.63 +/- 0.51 mmol/L (P = 0.031) and in men from 5.93 +/- 0.89 to 5.28 +/- 0.82 mmol/L (P = 0.045). Side-effects included mainly headache, nausea, and dizziness. One side-effect or more occurred transiently and with mild intensity in 14 patients. No patient discontinued the therapy because of side- effects. In conclusion, CV 205-502 appears to be a safe and valuable compound in the treatment of patients with PRL-secreting macroadenomas.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
J Kreutzer, R Buslei, H Wallaschofski, B Hofmann, C Nimsky, R Fahlbusch, and M Buchfelder
Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
Eur. J. Endocrinol., January 1, 2008; 158(1): 11 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Barlier and P. Jaquet
Quinagolide - a valuable treatment option for hyperprolactinaemia
Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society